Characteristics, Outcomes, and Clinical Indicators of Bloodstream Infections in Neutropenic Patients with Hematological Malignancies: A 7-Year Retrospective Study

References

• Amanati A, Sajedianfard S, Khajeh S, et al. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance. BMC Infect Dis. 2021;21(1):636. doi:10.1186/s12879-021-06243-z
   PubMed Web of Science ®Google Scholar
• Ma Y, Wang S, Yang M, Bao J, Wang C. Analysis of risk factors and clinical indicators in bloodstream infections among patients with hematological malignancy. Cancer Manag Res. 2020;12:13579–13588. doi:10.2147/CMAR.S289291
   PubMed Web of Science ®Google Scholar
• Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42(8):1749–1755. doi:10.1097/CCM.0000000000000330
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–2266. doi:10.1002/cncr.21847
   PubMed Web of Science ®Google Scholar
• De Socio GV, Garcia-Vidal C, Cardozo-Espinola C, et al. Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. PLoS One. 2018;13(6):e0199531.
   PubMed Web of Science ®Google Scholar
• Mattei D, Baretta V, Mazzariol A, et al. Characteristics and outcomes of bloodstream infections in a tertiary-care pediatric hematology-oncology unit: a 10-year study. J Clin Med. 2022;11(3):880. doi:10.3390/jcm11030880
   PubMed Web of Science ®Google Scholar
• Ma Y, Wen X, Kong Y, et al. Identification of new peptide biomarkers for bacterial bloodstream infection. Proteom Clin Appl. 2020;14(2):e1900075. doi:10.1002/prca.201900075
   PubMed Web of Science ®Google Scholar
• Shao I, Elkind M, Boehme A. Risk factors for stroke in patients with sepsis and bloodstream infections. Stroke. 2019;50(5):1046–1051. doi:10.1161/STROKEAHA.118.023443
   PubMed Web of Science ®Google Scholar
• El Haddad H, Chaftari A, Hachem R, Chaftari P, Raad I. Biomarkers of sepsis and bloodstream infections: the role of procalcitonin and proadrenomedullin with emphasis in patients with cancer. Clin Infect Dis. 2018;67(6):971–977. doi:10.1093/cid/ciy331
   PubMed Web of Science ®Google Scholar
• Mercier J, Ouldali N, Melki I, et al. Severe acute respiratory syndrome coronavirus 2-related multisystem inflammatory syndrome in children mimicking Kawasaki disease. Archiv Cardiovasc Dis. 2021;114(5):426–433. doi:10.1016/j.acvd.2021.04.005
   PubMed Web of Science ®Google Scholar
• Schwameis M, Steiner M, Schoergenhofer C, et al. D-dimer and histamine in early stage bacteremia: a prospective controlled cohort study. Eur J Intern Med. 2015;26(10):782–786. doi:10.1016/j.ejim.2015.10.024
   PubMed Web of Science ®Google Scholar
• Lameire N, Van Biesen W, Vanholder R. Electrolyte disturbances and acute kidney injury in patients with cancer. Semin Nephrol. 2010;30(6):534–547. doi:10.1016/j.semnephrol.2010.09.002
   PubMed Web of Science ®Google Scholar
• Di Domenico E, Marchesi F, Cavallo I, et al. The impact of bacterial biofilms on end-organ disease and mortality in patients with hematologic malignancies developing a bloodstream infection. Microbiol Spectr. 2021;9(1):e0055021. doi:10.1128/Spectrum.00550-21
   PubMed Web of Science ®Google Scholar
• Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004;39(s1):S25–S31. doi:10.1086/383048
   PubMedGoogle Scholar
• Chen C, Tang J, Hsueh P, et al. Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. J Form Med Assoc. 2004;103(7):526–532.
   PubMed Web of Science ®Google Scholar
• Rolston K. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40(Supplement_4):S246–S252. doi:10.1086/427331
   PubMedGoogle Scholar
• Marin M, Gudiol C, Ardanuy C, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. J Infect. 2014;69(5):417–423. doi:10.1016/j.jinf.2014.05.018
   PubMed Web of Science ®Google Scholar
• Shao S, Cong H, Wang M, Liu P. The diagnostic roles of neutrophil in bloodstream infections. Immunobiology. 2020;225(1):151858. doi:10.1016/j.imbio.2019.10.007
   PubMed Web of Science ®Google Scholar
• Zhu S, Kang Y, Wang W, Cai L, Sun X, Zong Z. The clinical impacts and risk factors for non-central line-associated bloodstream infection in 5046 intensive care unit patients: an observational study based on electronic medical records. Crit Care. 2019;23(1):52. doi:10.1186/s13054-019-2353-5
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo L, Song W, Wang Y, Dong F, GJBid L. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients. BMC Infect Dis. 2018;18(1):248.
   PubMed Web of Science ®Google Scholar
• Lien M, Chou C, Lin C, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospective cohort study. PLoS One. 2018;13(6):e0197851. doi:10.1371/journal.pone.0197851
   PubMed Web of Science ®Google Scholar
• Yao J, Li N, Jiang J. Clinical characteristics of bloodstream infections in pediatric acute leukemia: a single-center experience with 231 patients. Chin Med J. 2017;130(17):2076–2081. doi:10.4103/0366-6999.213411
   PubMed Web of Science ®Google Scholar
• Chen CY, Tien FM, Sheng WH, et al. Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008–2013. Int J Antimicrob Agents. 2017;49(3):272–281. doi:10.1016/j.ijantimicag.2016.11.009
   PubMed Web of Science ®Google Scholar
• Carvalho AS, Lagana D, Catford J, Shaw D, Bak N. Bloodstream infections in neutropenic patients with haematological malignancies. Infect Dis Health. 2020;25(1):22–29. doi:10.1016/j.idh.2019.08.006
   PubMed Web of Science ®Google Scholar
• R F. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents. 2008;32:S30–S33. doi:10.1016/j.ijantimicag.2008.06.017
   PubMed Web of Science ®Google Scholar
• Mutnick A, Kirby J, Jones R. CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy alliance for neutropenics and the control of emerging resistance. Ann Pharmacother. 2003;37(1):47–56. doi:10.1345/aph.1C292
   PubMed Web of Science ®Google Scholar
• Knight T, Glaser D, Ching N, Melish M. Antibiotic susceptibility of bloodstream isolates in a pediatric oncology population: the case for ongoing unit-specific surveillance. J Pediatr Hematol Oncol. 2019;41(5):e271–e276. doi:10.1097/MPH.0000000000001498
   PubMed Web of Science ®Google Scholar
• Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence. 2016;7(3):280–297. doi:10.1080/21505594.2016.1156821
   PubMed Web of Science ®Google Scholar
• Nesher L, Rolston K. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection. 2014;42(1):5–13. doi:10.1007/s15010-013-0525-9
   PubMed Web of Science ®Google Scholar
• Zhu J, Li Q, Li X, et al. Successful control of the first carbapenem-resistant Klebsiella pneumoniae outbreak in a Chinese hospital 2017–2019. Antimicrob Resist Infect Cont. 2020;9(1):91. doi:10.1186/s13756-020-00757-y
   PubMed Web of Science ®Google Scholar
• Righi E, Peri A, Harris P, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(3):668–677. doi:10.1093/jac/dkw459
   PubMed Web of Science ®Google Scholar
• Andria N, Henig O, Kotler O, et al. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. J Antimicrob Chemother. 2015;70(11):3146–3153. doi:10.1093/jac/dkv218
   PubMed Web of Science ®Google Scholar
• Moghnieh R, Estaitieh N, Mugharbil A, et al. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis. Front Cell Infect Microbiol. 2015;5:11. doi:10.3389/fcimb.2015.00011
   PubMed Web of Science ®Google Scholar
• Tofas P, Skiada A, Angelopoulou M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases. Int J Antimicrob Agents. 2016;47(4):335–339. doi:10.1016/j.ijantimicag.2016.01.011
   PubMed Web of Science ®Google Scholar
• Blennow O, Ljungman P. The challenge of antibiotic resistance in haematology patients. Br J Haematol. 2016;172(4):497–511. doi:10.1111/bjh.13816
   PubMed Web of Science ®Google Scholar
• Trecarichi E, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27(2):200–210. doi:10.1097/QCO.0000000000000038
   PubMed Web of Science ®Google Scholar
• Perez F, Adachi J, Bonomo R. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis. 2014;59(suppl_5):S335–339. doi:10.1093/cid/ciu612
   PubMedGoogle Scholar
• Trecarichi E, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21(4):337–343. doi:10.1016/j.cmi.2014.11.022
   PubMed Web of Science ®Google Scholar
• Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, et al. Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance. Clin Infect Dis. 2020;70(6):1068–1074. doi:10.1093/cid/ciz319
   PubMed Web of Science ®Google Scholar
• Yu Z, Pang X, Wu X, Shan C, S J, Miyamoto A. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS One. 2018;13(7):e0201667. doi:10.1371/journal.pone.0201667
   PubMed Web of Science ®Google Scholar
• Yang M, Choi S, Lee J, et al. Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies. PLoS One. 2019;14(12):e0225765. doi:10.1371/journal.pone.0225765
   PubMed Web of Science ®Google Scholar
• Svaldi M, Hirber J, Lanthaler A, et al. Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. Br J Haematol. 2001;115(1):53–57. doi:10.1046/j.1365-2141.2001.03083.x
   PubMed Web of Science ®Google Scholar
• Holzheimer R. Oral antibiotic prophylaxis can influence the inflammatory response in aortic aneurysm repair: results of a randomized clinical study. J Chemother. 2003;15(2):157–164. doi:10.1179/joc.2003.15.2.157
   PubMed Web of Science ®Google Scholar
• de Bont E, Vellenga E, Swaanenburg J, Kamps W. Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever? Infection. 2000;28(6):398–400. doi:10.1007/s150100070014
   PubMed Web of Science ®Google Scholar
• von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23(7):539–544. doi:10.1007/s10096-004-1156-y
   PubMed Web of Science ®Google Scholar
• Engel A, Steinbach G, Kern P, Kern W. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis. 1999;31(2):185–189. doi:10.1080/003655499750006254
   PubMedGoogle Scholar
• Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999;18(4):283–285. doi:10.1007/s100960050277
   PubMed Web of Science ®Google Scholar
• Sartori M, Zurlo C, Bon M, et al. Platelet-derived microparticles bearing PF4 and anti-GAGS immunoglobulins in patients with sepsis. Diagnostics. 2020;10(9):627.
   Web of Science ®Google Scholar
• Hannachi N, Lepidi H, Fontanini A, et al. A novel approach for detecting unique variations among infectious bacterial species in endocarditic cardiac valve vegetation. Cells. 2020;9(8). doi:10.3390/cells9081899
   PubMed Web of Science ®Google Scholar